RxDoctor Payments Data

Rebecca Adochio, MD

Endocrinology, Diabetes & Metabolism · Edwards, CONPI 1932255510

Payments from drug & device makers

$852in general payments, 2019–2025

Across 35 payments — averaging $24.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$302
  • Dexcom, Inc.$124
  • Tandem Diabetes Care, Inc.$116
  • BETA Bionics, Inc.$47
  • AbbVie$39
  • Lilly USA, LLC$36
  • plus $189 from 10 others

What the payments were for

  • Food & beverage$852100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$852 in reported general payments places this provider in the 40th percentile of 120 endocrinology, diabetes & metabolism providers in Colorado.

See all endocrinology, diabetes & metabolism providers in Colorado

Medicare billing

Part B allowed, 2024
$131,076
Medicare patients
346
Services billed
2,805

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TymlosAbaloparatide64$196,614
ForteoTeriparatide27$128,633
OzempicSemaglutide62$87,661
JardianceEmpagliflozin68$81,594
MounjaroTirzepatide37$47,473
TrulicityDulaglutide26$35,713
Tresiba Flextouch U-200Insulin Degludec14$31,177
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/725$28,430
TradjentaLinagliptin22$22,541
FiaspInsulin Aspart (Niacinamide)15$19,166
Fiasp FlextouchInsulin Aspart (Niacinamide)30$17,449
Tresiba Flextouch U-100Insulin Degludec23$10,849
SynthroidLevothyroxine Sodium66$4,832
NovologInsulin Aspart12$3,932
Nano 2nd Gen Pen NeedlePen Needle, Diabetic18$3,905

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCForteo, Mounjaro, Trulicity, Insulin Lispro$36$213,902112 claims
Novo NordiskOzempic, Fiasp, Novolog$35$110,75989 claims
AbbVieSynthroid$39$4,83266 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 120 endocrinology, diabetes & metabolism providers in Colorado.

Other endocrinology, diabetes & metabolism in Edwards

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →